Defining head and neck squamous cell carcinoma (HNSCC) prognostic and predictive biomarkers is anticipated to provide insights Into molecular contributors to disease progression and to contribute to HNSCC disease control. An ongoing effort by the Head and Cancer Program at the University of Pittsburgh has collected peripheral blood DNA from HNSCC cases and controls and demographic and tobacco use data beginning In 2000;tumor tissues have also been archived. Clinical, pathologic, and follow-up data continues to be collected for these 790 HNSCC cases. In addition to this large specimen and data collection, we have high-through-put genomic and proteomic technologies and expertise. We are therefore uniquely poised to evaluate biomarkers associated with HNSCC risk and prognosis. Epidermal growth factor receptor (EGFR) and gastrin-releasing peptide receptor (GRPR) are strongly implicated In HNSCC development/progression. Dr. Egloff proposes to: (1) determine whether EGFR/GRPR genetic variants are related to developing HNSCC using a case-control study;(2) determine whether EGFR/GRPR polymorphisms are prognostic indicators for HNSCC;and (3) evaluate correlations between HNSCC protein levels and EGFR/GRP R variant genotypes. These studies will be carried out with a carefully selected team of mentors and advisors who will provide expertise and guidance covering all aspects of the proposed studies. Dr. Egloff is an Assistant Professor in the Department of Otolaryngology, University of Pittsburgh with experience in translational research and formal training in cancer epidemiology and genetics. The candidate has outlined a career development plan including formal training in statistical genetics designed to facilitate her transition to an independent molecular epidemiologist cancer researcher.
The proposed studies will test the overall hypothesis that EGFR and GRPR genetic variants contribute to HNSCC risk and disease progression and are designed to gain insights into the molecular etiology of HNSCC and to define populations at risk for developing HNSCC and/or worse disease prognosis. Results of these studies are anticipated to inform treatment decisions and contribute significantly to HNSCC disease control.
|Lei, Yu; Lui, Vivian W Y; Grandis, Jennifer R et al. (2014) Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma. PLoS One 9:e85619|
|Egloff, Ann Marie; Lee, Ju-Whei; Langer, Corey J et al. (2014) Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res 20:5041-51|
|Gross, Andrew M; Orosco, Ryan K; Shen, John P et al. (2014) Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet 46:939-43|
|Egloff, Ann Marie; Liu, Xuwan; Davis, Autumn L Gaither et al. (2013) Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma. Head Neck 35:270-9|
|Wheeler, Sarah; Siwak, Doris R; Chai, Raymond et al. (2012) Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 18:2278-89|
|Egloff, Ann Marie; Gaither Davis, Autumn; Shuai, Yongli et al. (2012) Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respir Res 13:9|